LONGEVA.

ARA-290: adverse events and evidence limits

The four-week intravenous ARA-290 pilot in sarcoidosis with small-fiber neuropathy symptoms reported no observed adverse events. [1]

This small trial cannot establish rare-event frequencies or long-term risks. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Adverse events overallPatients with sarcoidosis and small-fiber neuropathy symptoms, intravenous, four-week pilot trialNo observed adverse events were reported; the small trial cannot establish rare-event frequencies or long-term risks[1]

References

  1. Lara Heij et al. (2012). Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study. 10.2119/molmed.2012.00332.